Nurix Therapeutics Announces 2024 Annual Meeting of Stockholders
Ticker: NRIX · Form: DEF 14A · Filed: Mar 27, 2024 · CIK: 1549595
Sentiment: neutral
Topics: Nurix Therapeutics, Annual Meeting, Proxy Statement, DEF 14A, Stockholder Vote
TL;DR
<b>Nurix Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on May 20, 2024, to elect directors, ratify auditors, and vote on executive compensation.</b>
AI Summary
Nurix Therapeutics, Inc. (NRIX) filed a Proxy Statement (DEF 14A) with the SEC on March 27, 2024. The 2024 Annual Meeting of Stockholders for Nurix Therapeutics, Inc. will be held virtually on May 20, 2024. The meeting will include the election of two Class I directors for three-year terms. Stockholders will vote on ratifying the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2024. An advisory vote will be held to approve the compensation of named executive officers. The meeting will be conducted virtually via live audio webcast, accessible at www.virtualshareholdermeeting.com/NRIX2024.
Why It Matters
For investors and stakeholders tracking Nurix Therapeutics, Inc., this filing contains several important signals. This virtual meeting format aims to increase stockholder attendance and participation globally. Key governance matters, including director elections and executive compensation approval, will be addressed, impacting corporate oversight.
Risk Assessment
Risk Level: low — Nurix Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement (DEF 14A) and does not contain new financial or operational disclosures that would indicate significant risk.
Analyst Insight
Stockholders should review the proxy materials to understand the proposals and exercise their voting rights for director elections and executive compensation.
Key Numbers
- 2 — Directors to be elected (Election of two Class I directors)
- 3 — Year term (Directors to serve three-year terms)
- 2024 — Fiscal Year (Fiscal year for which accounting firm is being ratified)
Key Players & Entities
- Nurix Therapeutics, Inc. (company) — Registrant name
- May 20, 2024 (date) — Date of Annual Meeting
- PricewaterhouseCoopers LLP (company) — Independent registered public accounting firm
- November 30, 2024 (date) — Fiscal year end for accounting firm ratification
- www.virtualshareholdermeeting.com/NRIX2024 (url) — Link to virtual meeting
FAQ
When did Nurix Therapeutics, Inc. file this DEF 14A?
Nurix Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on March 27, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Nurix Therapeutics, Inc. (NRIX).
Where can I read the original DEF 14A filing from Nurix Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Nurix Therapeutics, Inc..
What are the key takeaways from Nurix Therapeutics, Inc.'s DEF 14A?
Nurix Therapeutics, Inc. filed this DEF 14A on March 27, 2024. Key takeaways: The 2024 Annual Meeting of Stockholders for Nurix Therapeutics, Inc. will be held virtually on May 20, 2024.. The meeting will include the election of two Class I directors for three-year terms.. Stockholders will vote on ratifying the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2024..
Is Nurix Therapeutics, Inc. a risky investment based on this filing?
Based on this DEF 14A, Nurix Therapeutics, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement (DEF 14A) and does not contain new financial or operational disclosures that would indicate significant risk.
What should investors do after reading Nurix Therapeutics, Inc.'s DEF 14A?
Stockholders should review the proxy materials to understand the proposals and exercise their voting rights for director elections and executive compensation. The overall sentiment from this filing is neutral.
How does Nurix Therapeutics, Inc. compare to its industry peers?
Nurix Therapeutics operates in the pharmaceutical preparations industry, focusing on developing therapies.
Are there regulatory concerns for Nurix Therapeutics, Inc.?
The filing is made under SEC Rule 14a-101, requiring specific disclosures for proxy statements related to annual meetings.
Risk Factors
- Proxy Statement Filing [low — regulatory]: The filing is a Definitive Proxy Statement (DEF 14A) required by the SEC, detailing corporate governance matters.
Industry Context
Nurix Therapeutics operates in the pharmaceutical preparations industry, focusing on developing therapies.
Regulatory Implications
The filing is made under SEC Rule 14a-101, requiring specific disclosures for proxy statements related to annual meetings.
What Investors Should Do
- Review the proxy statement for details on director nominees and their qualifications.
- Understand the advisory vote on executive compensation and its implications.
- Ensure access to the virtual meeting platform using the control number from the proxy card.
Key Dates
- 2024-05-20: Annual Meeting of Stockholders — Key date for voting on corporate matters.
Year-Over-Year Comparison
This is a DEF 14A filing for the 2024 Annual Meeting, following the standard disclosure requirements for such events.
Filing Stats: 4,531 words · 18 min read · ~15 pages · Grade level 14.3 · Accepted 2024-03-27 07:01:07
Filing Documents
- ny20018253x1_def14a.htm (DEF 14A) — 883KB
- ny20018253x1_barchart01.jpg (GRAPHIC) — 158KB
- ny20018253x1_barchart02.jpg (GRAPHIC) — 147KB
- ny20018253x1_chart01.jpg (GRAPHIC) — 251KB
- ny20018253x1_piechart01x2.jpg (GRAPHIC) — 74KB
- ny20018253x1_pc01.jpg (GRAPHIC) — 575KB
- ny20018253x1_pc02.jpg (GRAPHIC) — 539KB
- sig_arthursandsx1.jpg (GRAPHIC) — 16KB
- 0001140361-24-015447.txt ( ) — 3308KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT ​ ​ 20 EXECUTIVE OFFICERS ​ ​ 22
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION ​ ​ 23 Executive Summary ​ ​ 23 Compensation Determination Process ​ ​ 25 Elements of Our Executive Compensation Program ​ ​ 27 Other Compensation Practices and Policies ​ ​ 29 COMPENSATION TABLES ​ ​ 31 Summary Compensation Table ​ ​ 31 Outstanding Equity Awards at 2023 Fiscal Year End ​ ​ 32 Pay versus Performance ​ ​ 33 Potential Payments upon Termination or Change in Control ​ ​ 35 EQUITY COMPENSATION PLAN INFORMATION ​ ​ 38 CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS ​ ​ 39 Policies and Procedures for Related-Party Transactions ​ ​ 39 ADDITIONAL INFORMATION ​ ​ 40 Stockholder Proposals and Director Nominations to be Presented at Next Annual Meeting ​ ​ 40 Delinquent Section 16(a) Reports ​ ​ 40 Available Information ​ ​ 40 “Householding” - Stockholders Sharing the Same Address ​ ​ 40 OTHER MATTERS ​ ​ 41 TABLE OF CONTENTS NURIX THERAPEUTICS, INC. 1700 Owens Street, Suite 205 San Francisco, California, 94158 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS   May 20, 2024 INFORMATION ABOUT SOLICITATION AND VOTING The accompanying proxy is solicited on behalf of the Board of Directors of Nurix Therapeutics, Inc. (Nurix, the company, we, us, or our) for use at Nurix’s 2024 Annual Meeting of Stockholders (Annual Meeting) to be held via a virtual meeting. You will be able to participate in the Annual Meeting and vote during the Annual Meeting via live webcast by visiting www.virtualshareholdermeeting.com/NRIX2024 on Monday, May 20, 2024, at 9:30 a.m. (Pacific Time), and any adjournment or postponement thereof. You will need the control number included